124605-42-1 Methyl(2R,3S)-3-(tert-butoxycarbonylamino)-2-hydroxy-3-phenylpropionate 98%

As a research-driven pharmaceutical manufacturing organization, Laurus Labs has been developing and assisting its client organizations to succeed in innovative medicines that globally enhance the health outcomes for patients.
Since our inception in 2005, we have been developing and manufacturing Active Pharmaceutical Ingredients (APIs) and Intermediates. We quickly scaled our pharmaceutical value chain by attaining a global leadership position in APIs, including anti-retroviral (ARV), Oncology, Cardiovascular, and Gastro therapeutics. Our position was strengthened by our backward-integration capability while remaining highly regulatory compliant across all operations.

As our portfolio of pharmaceutical Ingredients & Finished Dosages was strengthened, in line with our vision, Laurus Labs extended its development and manufacturing solutions to multiple large pharmaceutical organizations.

We emerged as one of the most trusted and largest pharmaceutical Contract Development & Manufacturing Organizations (CDMO) in India for both generics and the proprietary space.

While small-molecule chemistry is ingrained in our DNA, Laurus Labs recognizes the potential and differential benefits of large molecules, namely biologicals and biotechnology products, in the healthcare and nutritional space. We permeated this domain with the inception of Laurus Bio and continue the commitment by investing and collaborating in Cell and Gene therapies.

As a company, we are committed to conducting our business with utmost transparency, integrity, and responsibility towards our employees, society, customers, and all our stakeholders. We consciously and consistently strive to achieve our sustainable development goals, as showcased in our Environmental, Social, and Governance (ESG) focus and performance.